Abstract
Homomeric α7 nicotinic acetylcholine receptors (nAChRs) are implicated in the regulation of cognitive processes such as memory and attention and have potential as therapeutic targets for the treatment of the cognitive deficits associated with schizophrenia. Though numerous α7 nAChR agonists have been developed, and several have progressed to clinical trials, these are derived from few common chemotypes. Consequently, many of these α7 nAChR clinical candidates share unfavorable side-effect profile. SEN12333 represents a novel chemotype for the development of α7 nAChR agonists, and exploration of this scaffold has produced structurally diverse ligands with promising pharmacological properties. This review will summarize structure-affinity and -activity relationships surrounding analogs of SEN12333.
Keywords: Nicotinic receptors, schizophrenia, Alzheimer’s disease, SEN12333.
Current Pharmaceutical Design
Title:The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases
Volume: 22 Issue: 14
Author(s): Corinne Beinat, Samuel D. Banister, Marco Herrera and Michael Kassiou
Affiliation:
Keywords: Nicotinic receptors, schizophrenia, Alzheimer’s disease, SEN12333.
Abstract: Homomeric α7 nicotinic acetylcholine receptors (nAChRs) are implicated in the regulation of cognitive processes such as memory and attention and have potential as therapeutic targets for the treatment of the cognitive deficits associated with schizophrenia. Though numerous α7 nAChR agonists have been developed, and several have progressed to clinical trials, these are derived from few common chemotypes. Consequently, many of these α7 nAChR clinical candidates share unfavorable side-effect profile. SEN12333 represents a novel chemotype for the development of α7 nAChR agonists, and exploration of this scaffold has produced structurally diverse ligands with promising pharmacological properties. This review will summarize structure-affinity and -activity relationships surrounding analogs of SEN12333.
Export Options
About this article
Cite this article as:
Beinat Corinne, Banister D. Samuel, Herrera Marco and Kassiou Michael, The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases, Current Pharmaceutical Design 2016; 22 (14) . https://dx.doi.org/10.2174/1381612822666160127114125
DOI https://dx.doi.org/10.2174/1381612822666160127114125 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Resveratrol and Cancer: Chemoprevention, Apoptosis, and Chemoimmunosensitizing Activities
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors
Current Medicinal Chemistry Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry NMDA Receptors in Glial Cells: Pending Questions
Current Neuropharmacology Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design The Plasma Membrane: A Target and Hurdle for the Development of Anti- A? Drugs?
Current Drug Targets - CNS & Neurological Disorders The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Current Drug Targets Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research